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Abstract: Background: Treatment of malignancies is still a major challenge in human and canine cancer,
mostly due to the emergence of multidrug resistance (MDR). One of the main contributors of MDR is
the overexpression P-glycoprotein (Pgp), which recognizes and extrudes various chemotherapeutics
from cancer cells. Methods: To study mechanisms underlying the development of drug resistance,
we established an in vitro treatment protocol to rapidly induce Pgp-mediated MDR in cancer cells.
Based on a clinical observation showing that a 33-day-long, unplanned drug holiday can reverse the
MDR phenotype of a canine diffuse large B-cell lymphoma patient, our aim was to use the established
assay to prevent the emergence of drug resistance in the early stages of treatment. Results: We showed
that an in vitro drug holiday results in the decrease of Pgp expression in MDR cell lines. Surprisingly,
celecoxib, a known COX-2 inhibitor, prevented the emergence of drug-induced MDR in murine and
canine lymphoma cell lines. Conclusions: Our findings suggest that celecoxib could significantly
improve the efficiency of chemotherapy by preventing the development of MDR in B-cell lymphoma.
Keywords: lymphoma; multidrug resistance; P-glycoprotein; drug holiday; COX-2 inhibitors; celecoxib
1. Introduction
Despite newly developed therapies and protocols, treatment of lymphomas mostly results in
transient remission because of the rapid emergence of therapy resistance [1]. Dogs have shared a common
environment with humans for thousands of years. Canine lymphomas and human non-Hodgkin
lymphomas (NHLs) show strong similarities in genetics, therapy response, histopathology, and disease
progression [1–5]. Spontaneously occurring canine lymphoma has been considered a comparative animal
model to study mechanisms underlying therapy resistance and to investigate novel therapeutic agents
for human NHLs [6,7].
Canine lymphoma is usually treated with multiagent chemotherapy, such as the CHOP-protocol
(cyclophosphamide (C), doxorubicin (H, hydroxydaunorubicin), vincristine (O, Oncovin), and prednisone
(P)). Although this treatment regimen initially seems successful, tumor recurrence can be expected and
the relapsed tumor is often resistant to additional treatment. Cancer cells can become therapy-resistant
through multiple mechanisms that include changes in drug metabolism, the decreased uptake of
chemotherapy agents, increased DNA repair, and inhibition of apoptotic pathways [1,8]. One of the most
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common mechanisms is based on the active efflux of drugs from the cells mediated by transport proteins
of the ATP (adenosine triphosphate)-binding cassette (ABC) superfamily, including P-glycoprotein (Pgp,
ABCB1 (ATP-Binding Cassette Subfamily B Member 1)), MRP1 (Multidrug Resistance-Associated Protein
1) (ABCC1 (ATP Binding Cassette Subfamily C Member 1)), and BCRP (Breast Cancer Resistance Protein)
(ABCG2 (ATP-binding Cassette Subfamily G Member 2)). Pgp extrudes a wide spectrum of cytotoxic
compounds from the cell, resulting in decreased intracellular drug concentrations [8–10]. Several
classes of anticancer drugs used in human and veterinary medicine are substrates for Pgp [11]. Studies
have repeatedly linked the overexpression of P-glycoprotein to drug-resistant canine cancers [8,12,13].
Expression of Pgp was demonstrated in mast cell tumors [14], mammary tumors [15], pulmonary
carcinoma [16], and lymphoma [17,18]. Recently, we determined the impact of Pgp function on therapy
response and survival in canine lymphoma, using a quantitative measure based on the Pgp-mediated
efflux of calcein AM (acetoxymethyl) [19]. In agreement with studies measuring the Pgp-mediated efflux
of rhodamine 123 [20], our results confirmed the negative effect of P-glycoprotein function on therapy
response and survival [21].
Drug holidays have been proposed to limit the development of resistance in cancer treatment [22].
According to this concept, resistance can be reversed by introducing a pause in the treatment. In absence
of chemotherapy, adaptations driving resistance often prove to be a disadvantage, providing a new
selection pressure against resistant populations. The molecular basis of the negative selection during
drug holidays is not known. Reversal of therapy resistance is believed to be linked to reversible,
nonmutational changes. However, the required length of drug holiday in different cancer types
is not precisely established because only a few clinical studies are available [22,23]. In leukemia
cells, Pgp is rapidly induced by vincristine treatment, but after drug removal the expression of
Pgp was shown to return to initial levels [24]. This reversibility indicates a regulatory mechanism
that can switch the expression of MDR (multidrug resistance) proteins on and off during periods of
treatment and drug holidays, respectively. Induction and silencing of Pgp expression may be explained
by epigenetic changes and/or transcription factor activation. Interestingly, drug resistance can be
modulated by the combination of epigenetic inhibitors such as histone deacetylase inhibitors (HDACis)
with chemotherapy [6,25–29]. Additionally, cyclooxygenase (COX)-2, a key enzyme responsible for
the synthesis of prostaglandins from arachidonic acid, was shown to influence Pgp expression. Cells
virally transduced with COX-2 show high levels of Pgp expression and rhodamine efflux activity,
however, the mechanistic link between COX-2 and Pgp remains to be identified [30].
To study mechanisms underlying the development of drug resistance and the effect of drug
holidays, we established an in vitro treatment protocol to rapidly induce Pgp-mediated MDR in cancer
cells. Our ultimate goal was to identify clinically relevant COX-2 and HDACis that may prevent or
delay the emergence of drug resistance during chemotherapy. Here we show that celecoxib, a potent
COX-2 inhibitor, prevents doxorubicin-induced MDR by inhibiting the expression of Pgp. Our findings
suggest that inclusion of celecoxib in the treatment protocols may significantly improve efficiency of
chemotherapy by preventing the development of MDR in B-cell lymphoma.
2. Results
2.1. Pgp-Mediated Drug Resistance Is Temporarily Reversed by a Drug Holiday: A Clinical Case Study of Two
Canine Lymphoma Patients
Two canine patients were diagnosed with B-cell lymphoma (Table S1). Both patients were treated
according to the modified CHOP protocol (Table S2). Multidrug resistance was quantitated by the
calcein assay and the activity of Pgp was expressed as a dimensionless value (multidrug resistance
activity factor (MAF)) [31].
Case 1 (Figure 1a): The calcein assay performed at the time of diagnosis indicated a lack of
P-glycoprotein activity (MAF = 0.01) in the treatment-naïve tumor cells of Patient 1. After 7 rounds of
treatment, the MAF value was 0.16 (day 51), which increased with an additional 4 rounds of treatment,
reaching MAF = 0.24 at day 93. Pgp function, characterized by repeated calcein assays performed on
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isolated tumor cells, showed further increase at day 184, after 9 additional rounds of chemotherapy,
reaching high levels (MAF = 0.56) usually observed in Pgp-overexpressing cell lines, such as HCT-15,
CHO K1, and HCT-8, exhibiting a MAF of 0.63, 0.64, and 0.46, respectively [32]. The immunophenotype
of the lymphoma remained identical during the course of the 184 days (Figure 1a).
Case 2 (Figure 1b): Tumor cells isolated from Patient 2 showed significant Pgp activity at the time
of diagnosis (MAF = 0.35), which further increased following 7 additional treatments (MAF = 0.52 at
day 135). At this point, due to financial reasons, the treatment was temporarily halted for 33 days.
Surprisingly, this unplanned drug holiday resulted in a significant decrease of Pgp activity (MAF =
0.22). However, following two additional cycles of treatment, tumor cells regained Pgp expression
(MAF = 0.31), indicating the re-emergence of the resistant phenotype at day 217. The immunophenotype
of the lymphoma remained identical during the course of the 217 days (Figure 1b).
Cancers 2020, 12, x 3 of 16 
 
treatment, the MAF value was 0.16 (day 51), which increased with an additional 4 rounds of 
treatment, reaching MAF = 0.24 at day 93. Pgp function, characterized by repeated calcein assays 
performed on isolated tumor cells, showed further increase at day 184, after 9 additional rounds of 
chemotherapy, reaching high levels (MAF = 0.56) usually observed in Pgp-overexpressing cell lines, 
such as HCT-15, CHO K1, and HCT-8, exhibiting a MAF of 0.63, 0.64, and 0.46, respectively [32]. The 
immunophenotype of the lymphoma remained identical during the course of the 184 days (Figure 
1a). 
Case 2 (Figure 1b): Tumor cells isolated from Patient 2 showed significant Pgp activity at the 
time of diagnosis (MAF = 0.35), which further increased follo ing 7 additional treatments (MAF = 
0.52 at day 135). At this point, due to financial reasons, the treatment was temporarily halted for 33 
days. Surprisingly, this unplanned drug holiday resulted in a significant decrease of Pgp activity 
(MAF = 0.22). However, following two additional cycles of treatment, tumor cells regained Pgp 
expression (MAF = 0.31), indicating the re-emergence of the resistant phenotype at day 217. The 
immunophenotype of the lymphoma remained identical during the course of the 217 days (Figure 
1b).  
 
Figure 1. Changes in P-glycoprotein function during chemotherapy in two B-cell lymphoma canine 
patients. P-glycoprotein activity, as determined by the calcein assay (MAF values), was monitored 
during therapy (treatments are indicated by arrows). Flow cytometry histograms show the calcein 
fluorescence of cancer cells incubated with (blue) and without (red) the Pgp inhibitor verapamil. (a) 
Patient 1 showed the typical kinetics of acquired multidrug resistance. (b) In the case of Patient 2, 
MDR was reversed by a 33-day-long (unplanned) drug holiday. The immunophenotype of the 
lymphoma remained identical during the treatment in both case (results show data of the final 
measurement). 
2.2. A Novel Assay to Study the Rapid Emergence of Drug Resistance and the Effect of Drug Holiday 
To study mechanisms underlying chemotherapy-induced drug resistance and renewed 
sensitivity following drug holidays, we established an in vitro assay based on the treatment of 
lymphoma cell lines. Our aim was to model clinical protocols by treating drug-naive cells with high 
concentrations of doxorubicin for 5 days, followed by culturing cells in drug-free medium. Treatment 
with IC10 (Inhibitory Concentration 10) of doxorubicin equals the concentration which kills 90% of 
the cells, however, surviving cells were able to recover and proliferate over time. After 3 cycles of 
doxorubicin (13 nm) treatment, P388 cells showed a significant increase in P-glycoprotein function 
(P388 D), evidenced by a dramatic increase of the MAF value (from 0.02 ± 0.02 to 0.68 ± 0.16). 
Intriguingly, a 32-day-long “drug holiday”, during which P388 D cells were cultured without 
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Figure 1. Changes in P-glycoprotein function during chemotherapy in two B-cell lymphoma canine
patients. P-glycoprotein activity, as determined by the calcein assay (MAF values), was monitored during
therapy (treatments are indicated by arrows). Flow cytometry histograms show the calcein fluorescence
of cancer cells incubated with (blue) and without (red) the Pgp inhibitor verapamil. (a) Patient 1 showed
the typical kinetics of acquired multidrug resistance. (b) In the case of Patient 2, MDR was reversed by a
33-day-long (unplanned) drug holiday. The immunophenotype of the lymphoma remained identical
during the treatment in both case (results show data of the final measurement).
2.2. A Novel Assay to Study the Rapid Emergence of Drug Resistance and the Effect of Drug Holiday
To study mechanisms underlying chemotherapy-induced drug resistance and renewed sensitivity
following drug holidays, we established an in vitro assay based on the treatment of lymphoma cell
lines. Our aim was to model cli ical protocols by r ating drug-naive cells with high concentrations
of doxorubicin for 5 days, fol owed by culturing cells in drug-free medium. Treatment with IC10
(Inhibitory Concentration 10) of doxorubicin equ ls the ncentration which kills 90% of the cells,
h w ve , surviving cells were able to recover and proliferate over time. After 3 cycles of doxorubicin
(13 nm) treatment, P388 c lls sh wed a significant i crease in P-glycop o ei fun tion (P388 D),
evidenced by a d amatic crease of the MAF value (f om 0.02 ± 0.02 t 0.68 ± 0.16). Intriguingly,
a 32-day-lo g “drug holiday”, during whic P388 D cells were cultured without doxorubicin (P388
D/DH), resulted in a decrease of the MAF value (0.47) (Figure 2a). In line with the observed changes
i P-glycoprotein activity, P388 D cells were 9.9-fold res stant to doxorubicin (DOX) (p < 0.0001),
while P388 D/DH cells showed only 3.6-fold resistance to DOX as compared to pare tal P388 cells
(Figure 2b). The direct involvement of Pgp in the acquired resistance of P388 D cells was verified
by the addition of the P-glycoprotein inhibit r tariquidar (TQ). In agreement with the functional
results, mRNA (messenger ribonucleic acid) expression of the mouse Abcb1a gene increased in P388 D
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(p < 0.0001) and decreased in P388 D/DH cells (p = 0.0003), while the expression of Abcb1b was equally
high in both treatment groups compared to P388 (p < 0.0001) (Figure 2c, Figure S1).
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Figure 2. Effect of doxorubicin treatment and drug holiday on mouse P388 lymphoblastic leukemia
cells. (a) Parental P388 cells were treated with 13 nM DOX. After 3 cycles of DOX treatment (42 days)
P388 D cells showed a significant increase in P-glycoprotein activity (MAF 0.6 vs. MAF 0.04), which
was significantly reduced after a 32-day-long drug holiday (MAF 0.47). Flow cytometry histograms
show the results of the calcein assay of cells assayed in the presence (red) or absence (black) of the Pgp
in ibitor verapamil. (b) Changes of d xorubicin sensitivity as a result of drug treatment nd drug
holiday. Sequential DOX treatments of P388 cells resulted in a 9.9-fold increase of doxorubici tolerance
(P388 D), which was significantly reduced following a drug holiday (P388 D/DH). Re istance of P388 D
cells was abrogated in the presence of tariquidar (P388 D + TQ) (c) Abcb1a and b mRNA expression
and DOX IC50 values (red dot ) of P388 parental cells (P388) after DOX treatment (D and following
drug holiday (D/DH). Statistical analysis was performed on mRNA samples, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.
Similar results were obtained with a canine B-cell lymphoma cell line: Parental CLBL-1 cells
express low levels of Pgp (MAF = 0.16 ± 0.03), which were signific ntly increased after 6 rounds of
doxorubicin treatment (MAF = 0.39 ± 0.05), resulting in th increased doxorubicin resistance of the
cells. Again, culturing of the cells for 27 days without doxorubicin decreased the MAF v lu t 0.3
(±0.04) and in reased the sensitivity f cells to doxorubicin (p = 0.0006) (Figure 3a,b).
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(a) After 6 cy les of DOX treatm n (74 d ys) parenta CLBL-1 cells showed a significant increase in
P-glycoprotein activity (MAF 0.42 vs. 0.22), which w s significant y reduc fter a 27-day-long drug
holiday (MAF 0.26). Flow cytometry histograms show the results of the alcein assay of cel s assayed
with (blue) or without (red) the Pgp inhibitor verapamil. (b) Changes of doxorubicin sensitivity as a
result of drug treatment and dru holiday. Sequential DOX tre tm nts of CLBL-1 cells resulted in
9.2-fold increase of doxorubicin tolerance, which w s significantly reduced following the period of
drug holiday. Resistance of CLBL-1 DOX cells was abro ated i the presence of tariquidar (D + TQ).
** p < 0.01; *** p < 0.001; ns: not significant.
2.3. Celecoxib Prevents the Development of Pgp-Mediated Drug Resistance In Vitro
As drug holidays are not routi ely introduced in therapies, we next tested drug combinations to
prevent or delay the emergence of acquired resistance. We chose three COX-2 inhibitors and two HDAC
(histone deacetylase) inhibitors that are routinely used in the veterinary practice. Drug-naive cells were
treated in 9 consecutive cycles either with DOX alone, or DOX in combination with subtoxic doses
(IC80) of SAHA (suberanilohydroxamic acid), trichostatin-A (TSA), celecoxib (CEL), firocoxib (FIR),
or meloxicam (MEL). Concentrations for each drug were selected in separate cytotoxicity experiments
as described in the Materials and Methods section (Figure S2). MAF was determined after every third
treatment. The median time to reach MAF 0.2 (considered as the threshold of resistance), was 40, 41, 51,
and 67 days for DOX + TSA (n = 3), DOX + SAHA (n = 3), DOX + MEL (n = 2) and DOX + FIR (n = 5),
respectively (Figure 4a, Figure S3). Surprisingly, celecoxib completely prevented the expression of
P-glycoprotein, as none of the DOX + CEL (n = 5) treated cultures reached the threshold of MAF = 0.2
during the 100-day-long experimental period compared to DOX (p = 0.0027, with hazard ratio = 27.38
and 95% CI (confidence interval) of ratio = 3.161 to 237.2) (Figure 4a,b).
The remarkable effect of CEL on DOX-induced MDR was further confirmed by drug sensitivity
tests performed on both cell lines after 9 cycles of treatment. In the case of P388 cells, DOX alone
resulted in a 160-fold increase in DOX resistance (IC50 = 0.01 µM untreated vs. IC50 = 1.6 µM DOX
treated) while addition of CEL prevented the emergence of doxorubicin resistance (IC50 remained
0.03 µM) even after 9 cycles of treatment for at least 100 days (Figure 4c). In CLBL-1 cells, the DOX
+ CEL treatment even resulted in a decrease of DOX sensitivity (IC50 = 0.44 µM untreated vs. IC50
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= 0.24 µM DOX + CEL treated), whereas DOX-treated cells were 4.5-fold resistant (IC50 = 1.99 µM)
(Figure 4d).
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Figure 4. Celecoxib prevented the emergence of Pgp-mediated drug resistance in both P388 and CLBL-1
cells. (a) Kaplan–Meier curves of cell cultures treated with the indicated combinations. Cells were
considered resistant at MAF ≥ 0.2. DOX (red) in combination with firocoxib (blue), celecoxib (green),
meloxicam (pink), trichostatin-A (brown), and SAHA (black) were treated in 9 sequential treatment
cycles. (b) Quantitative evaluation of multidrug resistance during the course of various treatments in
P388 and CLBL-1 cells. MAF was measured after every third treatment cycle (MAF1–3). (c,d) Relation
of MAF and drug sensitivity. MAF (patterned bars) and DOX IC50 values (red squares) of parental
(sensitive), DOX-treated, and DOX + CEL-treated (c) P388 cells, and (d) CLBL-1 cells, measured after 9
sequential treatment cycles (at around day 100). Statistical analysis was performed on MAF values,
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns: not significant.
2.4. Celecoxib Prevents the Emergence of Drug Resistance without Inhibiting Pgp or Contributing to the
Toxicity of DOX
We tested the effect of CEL on the calcein accumulation of P388/ADR cells, which overexpress
Pgp as a result of continuous drug selection [33]. While P388/ADR cells show low calcein fluorescence
(red) due to the Pgp-mediated efflux of calcein AM, the Pgp inhibitor verapamil restores fluorescence
by blocking dye efflux (blue). In contrast, CEL (up to 160 µM) had no effect on cellular fluorescence,
indicating that it does not inhibit Pgp (Figure 5a).
Interestingly, combined treatment with DOX + CEL significantly delayed the repopulation of the
flasks (8 and 22 days following treatment with DOX and DOX + CEL, respectively) (Figure S4). To rule
out synergistic toxicity, the toxicity of the combined treatment was evaluated in short-term toxicity
assays. Surprisingly, CEL and DOX proved to be antagonistic, rather than synergistic in both cell lines,
suggesting that the ability of CEL to prevent DOX-induced MDR is not due to the increased toxicity of
the combination treatment (Figure 5b,c).
To investigate the effect of CEL on Pgp expression, we cultured P388/ADR and CLBL-1 D cells
in the absence or presence of CEL. Treatment with CEL decreased the MAF of both cell lines slightly
more than the drug holiday (Figure 5d,e). In the case of P388/ADR cells, the MAF value changed
from 0.90 (±0.08) to 0.73 (±0.1) during the 28 days of the drug holiday, whereas cells treated with CEL
Cancers 2020, 12, 1117 7 of 16
exhibited a MAF 0.65 (±0.1) after a 28-day-long treatment (Figure 5d). Similar results were obtained
with CLBL-1 D cells (MAF 0.39 ± 0.05), exhibiting MAF = 0.30 (±0.04) following a drug holiday of
18 days, and MAF = 0.23 (±0.04) following an 18-day treatment with CEL (Figure 5e).
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3. Discussion
Lymphoma is responsible for a significant fraction of cancer mortality in canine and human
patients [1]. Novel strategies are urgently required to i crease tr at ent efficacy i the human and
ve erinary clinica p ctice. Anth acyc ine-based chemotherapy protocols are initially successful,
but tumor ells often be ome resistant [34]. Overexpression of P-gly prote result in multidr g
resistance and an unfavorabl response to therapy of cani e lymphoma patie ts [17,35].
Sev r l iffere t drug resistance mechanisms were identified in cancer [36]. Malignant cells can
metabolize drugs through the CYP (cytochrome P450) system [37], alter drug targets [38], increase
DNA repair to overcome DNA-damaging toxic insults [39], modify apoptotic pathways to avoid cell
death [40], undergo epithelial-to-mesenchymal transition [41], or use ra id epigenome m difications
to reversibly adopt drug sensitive and resistant phenotypes [42]. Pg can protect cancer cells by
reducing the intracellular concentrations of drugs b low a cell-killing threshold. Pgp recognizes a
wide array of currently used hemotherapeutics, but the extent to which it contributes to clinical
multid ug resistance has remained a matter of debate. Although the strategy of transporter inhibition
co ld not b validated in clin cal trials, mounting evidence continues o support the ole of Pgp i
linical multidrug r sistance n some settings [43]. Pgp ontributes to therapy resistance in acute
myeloid leukemia [44–46], ovarian and breast cancer [47,48], ependymoma [49], medulloblastom [50],
elanoma [51], and hepatocellular carcinom [52]. R cently, we and others h ve shown that resi ance
to anthracycline-based chemotherapy is almost universally based on the overexpression of Pgp in a
clinic lly relevant mouse mod l of heredita y breast cancer [53–57]. As a result of its b oad substrate
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specificity, Pgp also extrudes fluorescent dyes such as calcein AM [58,59]. Clinical studies have shown
that the calcein assay can be used as a quantitative, standardized, and inexpensive screening test in
a routine clinical laboratory setting to detect Pgp activity and to identify patients with unfavorable
therapy responses [31].
Using a functional assay, we followed the emergence of Pgp-mediated resistance in two canine
patients. As expected, we found that continuous chemotherapy induced drug resistance. Surprisingly,
in patient 2, a pause in the therapy resulted in a reversible reduction of resistance along with the
temporary resensitization of the tumor to the treatment (Figure 1). Several studies have reported similar
findings in human cancer patients, showing the beneficial effect of drug holidays on treatment efficiency.
Even after therapy failure, lung cancer patients were shown to respond to EGFR (Epidermal Growth
Factor Receptor) treatment following a short period of drug holiday [60,61]. Similarly, melanoma
patients who discontinue BRAF (B-Raf Proto-Oncogene)-directed therapy due to progression or other
causes can benefit from retreatment at a later stage [62]. The possible benefit of treatment rechallenge
with chemotherapy has also been described in canine patients [63]. In the veterinary practice, drug
holidays are typically inserted to reduce the toxic side effects of chemotherapy. The striking effect of
the short drug holiday observed in Patient 2 prompted us to set up an in vitro assay modelling the
development of clinical drug resistance and the effect of drug holiday on drug sensitivity.
In vitro models of Pgp-mediated MDR have been typically established by the stepwise selection
of cells in increasing concentrations of cytotoxic compounds [64,65]. Because of the lengthy selection
procedure, MDR cells such as P388/ADR [33] express extremely high levels of P-glycoprotein, and thus
do not provide a realistic model of clinical MDR. Here, we introduced a new approach for the study of
acquired resistance, in which treatment with high concentrations of toxic chemotherapy is followed
by recovery periods in drug-free medium. We found that repeated treatment cycles eventually led
to multidrug resistant cells that express moderate, clinically relevant levels of Pgp [53,57] (Figures 2
and 3). Using this protocol, we investigated the development of Pgp-mediated drug resistance and
the effects of drug holiday in a mouse lymphoblastic leukemia (P388) and a canine B-cell lymphoma
(CLBL-1) cell line. In line with clinical observations, we observed a rapid and reversible induction of
Pgp expression in both cells.
Following high-dose EGFR-inhibitor treatment of non-small cell lung cancer (NSCLC) cell
lines, a drug-tolerant “persister” population exhibiting reversible drug resistance can be consistently
detected [42]. Significantly, inhibition of the KDMA5a histone demethylase results in the selective
depletion of the persister subpopulation, leading to renewed sensitivity to EGFR inhibitors. Similarly,
persisters originating from T-cell acute lymphoblastic leukemia (T-ALL) rely on the chromatin modifier
protein BRD4, consistent with the benefit of the BRD4 inhibitor JQ1 in primary human leukemias [25].
These findings establish the rationale for incorporating epigenetic modulators in combination therapies.
To test the relevance of epigenetic regulatory mechanisms in the reversible induction of Pgp expression,
we repeated our experiments in the presence of clinically used epigenetic inhibitors (SAHA, TSA).
In contrast to our expectations, the inhibitors did not influence the emergence of acquired drug
resistance (Figure 4a). Hematological malignancies are particularly sensitive to HDACis [66], but for
our purposes the epigenetic inhibitors had to be administered at nontoxic concentrations (Figure S2),
which may have resulted in suboptimal concentrations.
Another clinically feasible approach to interfere with the drug-induced overexpression of Pgp may
rely on the inhibition of COX-2. Selective COX-2 inhibitors (i.e., celecoxib, firocoxib, or meloxicam) have
pro-apoptotic and anti-proliferative effects in human and canine tumors [67–70]. Interestingly, Pgp was
shown to mediate celecoxib-induced apoptosis by activating caspase-3 and increasing cytochrome
c release from the mitochondria [71]. In addition, immunohistochemical analyses of human breast
tumor specimens revealed a strong correlation between expression of COX-2 and Pgp [72]. Based
on mounting evidence supporting the link between COX-2 and Pgp-mediated drug resistance [30],
we tested a panel of clinically used COX-2 inhibitors in our assay.
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Strikingly, addition of celecoxib completely prevented the development of MDR in both cell lines
(Figure 4). Since celecoxib does not influence Pgp function (Figure 5a) or DOX toxicity (Figure 5b,c),
its ability to prevent MDR is likely mediated by repressing the expression of Pgp. Although COX-2 is
known to regulate Pgp expression via c-Jun phosphorylation [73] or PGE2 [74], lack of Pgp repression by
firocoxib or meloxicam indicates that the effect of celecoxib is independent from the inhibition of COX-2.
Inhibition of Pgp expression may be related to celecoxib’s many off-target effects, such as inhibition of
cancer-associated carbonic anhydrases [75], the master kinase PDK1 [76,77], or the sarco/endoplasmic
reticulum Ca2+-ATPase [78]. Future work will be needed to demonstrate whether this promising effect
can be exploited in the human and canine cancer clinic.
4. Materials and Methods
4.1. Drugs
Doxorubicin (DOX, Sigma-Aldrich, St. Louis, MO, USA), celecoxib (CEL, Sigma-Aldrich),
trichostatin-A (TSA, Tocris Bioscience, Bristol, UK), SAHA (Tocris Bioscience), and firocoxib (FIR,
Sigma-Aldrich) were purchased from the manufacturers. Meloxicam (MEL, Ceva, Libourne, France)
was a kind gift from Ceva Animal Health, LLC.
4.2. Cell Lines
The mouse leukemic P388 and its doxorubicin-selected subline P388/ADR were obtained from
the National Cancer Institute’s Developmental Therapeutics Program (National Institutes of Health).
The canine B-cell lymphoma CLBL-1 cell line was a kind gift from Dr. Barbara Rütgen (University
of Veterinary Medicine, Vienna) [3]. P388/ADR cells were maintained in 500 nmol/L doxorubicin
(Adriamycin, Sigma-Aldrich, St. Louis, MO, USA) to ensure Pgp expression. Cells were cultured in
RPMI (Roswell Park Memorial Institute) media (Life Technologies, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum, 5 mmol/L glutamine, and 50 units/mL penicillin and streptomycin (Life
Technologies). All cell lines were cultured at 37 ◦C with 5% CO2.
4.3. In Vitro Cell Viability Assay
To test the cytotoxicity of mono and combined treatments, cells were seeded into 96- or 384-well
tissue culture plates at 2500 (P388) or 100,000 (CLBL-1) cells/well density in 100 µL or 20 µL medium,
respectively. Drug combinations were added to the plates by a Hamilton StarLet liquid handling
workstation. The plates were incubated for 120 h at 37 ◦C with 5% CO2.
IC50 and growth inhibition (GI) values were assessed by the PrestoBlue® assay (ThermoFisher,
Waltham, MA, USA), according to the manufacturer’s instructions. Briefly, cells were plated in 96-
or 384-well plates, treated in the given concentration range with the indicated compounds. Viability
of the cells was measured spectrophotometrically using an EnSpire microplate reader (Perkin Elmer,
Waltham, MA, USA). Data were normalized to untreated cells; curves were fitted by the Graph Pad
Prism 8 software using the sigmoidal dose–response model. Curve fit statistics were used to determine
the selected IC values. In the case of the drug combinations, GI50 values of ‘compound 1’ with the fixed
concentrations of ‘compound 2’ (and vice versa) were paired, and plotted on an equipotent graph as
GI50 isoboles. For each data point of the isobole, significance was calculated as the combination index
(CI) [79]. Drug combinations were considered to indicate synergism (CI ≤ 0.7), moderate synergism
(0.7 < CI ≤ 0.85), additive (0.85 < CI ≤ 1.2), moderate antagonism (1.2 < CI ≤ 1.45), and antagonism
was defined as CI > 1.45, respectively.
4.4. In Vitro Model System to Study the Development of Drug Resistance
For every drug (except for doxorubicin and firocoxib), IC80 values (drug concentration which kills
approximately 20% of the cells) were determined for both cell lines using cytotoxicity assays. In the
case of doxorubicin, the concentration killing 90% of the cells (IC10) was used. Firocoxib, which was
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not toxic even at 1000 µM, was used at the concentration corresponding to the IC80 concentration of
celecoxib. P388 cells (106) were treated with 13 nM doxorubicin (DOX) for 120 h in T75 suspension flasks
(Sarstedt AG & Co. KG, Nümbrecht, Germany). When used in combination, DOX was complemented
with celecoxib (16 µM), firocoxib (16 µM), trichostatin-A (30 nM), or SAHA (0.4 µM). Following
incubation with the drugs, surviving cells were cultured further in drug-free medium. The medium
was changed every 5 days until the surviving cells reached the initial density of 106/18 mL (termed as
“repopulation”). Treatments were repeated multiple times; the emergence of P-glycoprotein-mediated
drug-resistance was followed by the calcein assay [80]; chemosensitivity of the cells was characterized
by cytotoxicity assays.
In case of CLBL-1 cells, the initial cell number was 107, and the treatment lasted for 120 h.
The following concentrations were used for each drug: DOX (0.3 nM), trichostatin-A (50 nM), SAHA
(0.7 µM), celecoxib (26 µM), firocoxib (26 µM), and meloxicam (20 µM).
4.5. Immunophenotyping of CLBL-1 Cells
The following antibodies (AbD Serotec, Kidlington, UK) were used to determine the
immunophenotype of the canine lymphomas by flow cytometry: CD3 FITC (clone CA17.2A12),
CD5 FITC (clone YKIX322.3), CD11/18 FITC (clone YKIX490), MHC II FITC (clone YKIX334.2), CD14
PE (clone, TÜK4), CD21 PE (clone CA2.1D6), CD34 PE (clone 1H6), and CD45 APC (clone YKIX716.13).
The same panel was used to verify the immunophenotype of the CLBL-1 cells (Table S3).
4.6. Determination of MDR Activity Factor (MAF) with the Calcein Assay
The 250,000 cells were incubated with 0.25 mmol/L calcein AM (Dojindo Molecular Technologies,
Rockville, MD, USA) in medium with or without 10 mmol/L verapamil for 10 min at 37 ◦C. Cells were
washed with ice-cold PBS, and calcein accumulation was measured with a FACScan or FACS Calibur
flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). Dead cells were excluded based on
7-AAD (7-aminoactinomycin D (Sigma-Aldrich, St. Louis, MO, USA) permeability.
For the clinical cases, lymphoid cells were collected during surgical biopsy under general
anesthesia or by fine-needle aspiration. Lymph node samples were immersed into dissociation medium
containing Dulbecco’s Modified Eagle Medium (DMEM), 200 U/mL collagenase type II, and 0.6 U/mL
dispase (Life Technologies, Carlsbad, CA, USA). After a 30-minute-long incubation at 37 ◦C, cells
were separated by a 40-µM cell strainer. Isolated cells were centrifuged at 300 g. Cells were selected
based on size and granularity; viable cells were gated based on 7-AAD exclusion. The 10,000 7-ADD
negative cells were analyzed. The activity of Pgp was expressed as a dimensionless value using the
mean fluorescence intensity measured in the presence and absence of verapamil (mean fluorescence
inhibited (MFI) and noninhibited (MFNI), respectively). The MAF was determined using the following
formula: MAF = (MFI − MFNI)/MFI [31,80].
4.7. RNA Isolation and RT-PCR
P388 cells were homogenized in TRIzol™ Reagent (Life Technologies). Total RNA was isolated
using Direct-zol® MiniPrep kit (Zymo Research, Irvine, CA, USA) according to the manufacturer’s
instructions. To prevent DNA contamination, in-column DNAse I treatment was used. Then, 300-ng
total RNA was reverse transcribed to cDNA using the Promega Reverse Transcription System Kit.
Abcb1a, Abcb1b, and Actin β (Actβ) mRNA levels were quantified by TaqMan® assays (ThermoFisher),
using the StepOne™ Real-Time PCR System (Life Technologies). The mRNA fold changes were
determined by the 2−∆∆Ct method.
4.8. Canine B-Cell Lymphoma Case Studies
Two canine patients diagnosed with B-cell lymphoma at the Veterinary Hematology and Oncology
Clinic (Budapest) were treated according to the modified CHOP protocol consisting of doxorubicin
(Adriamycin injection, Pharmacia & Upjohn S.p.A. Co., Milan, Italy) 30 mg/m2: week 2, 11, 20; vincristi
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(Vincristine liquid injection, Gedeon Richter Co., Budapest, Hungary) 0.75 mg/m2: week 1, 3–10, and
12–19; cyclophosphamide (Endoxan injection, Baxter Co., Deerfield, IL, USA) 250 mg/m2: week 5, 8, 14,
17; prednisolone (Prednisolone tablet, Gedeon Richter Co., Budapest, Hungary): 2 mg/kg BW (body
weight) week 1, perorally (po) daily, once a day (SID), 1.5 mg/kg BW week 2 po daily, SID, 1 mg/kg BW
week 3 po daily, SID, 0.5 mg/kg BW week 4, po daily, SID [81].
Case 1: German shepherd, male, 3.5 years old. Large cell immunoblastic lymphoma was diagnosed
in stage V (substage b). Case 2: Cocker spaniel, female, 6.5 years old. Diffuse large B-cell lymphoma
was diagnosed in stage IV (substage a). All dogs were staged and substaged according to the scheme
established by the World Health Organization (WHO) [82].
Initial diagnosis was made by chest X-ray, abdominal ultrasonography, complete blood count,
and routine plasma clinical chemistry analyses together with right prescapular lymph node excision
and bone marrow aspiration cytology based on the informed consent of the owner (Supplementary
Materials 1 and Methods 1). Histopathology and immunophenotyping of the tumor cells were
determined by FACS analysis of the excised lymph node. At the time of diagnosis, during treatment,
and at the end of chemotherapy, Pgp-mediated drug resistance was monitored by the calcein assay
and the immunophenotype of tumor cells was characterized by flow cytometry.
4.9. Statistical Analysis
Statistical analyses were performed using the GraphPad Prism version 8.0.0 for Windows,
GraphPad Software (San Diego, CA, USA). One-way or two-way ANOVA followed by Tukey’s
multiple test was used for comparisons between treatment groups and MAF values for each cell line.
The difference between Kaplan–Meier survival curves was determined by log-rank test. The p < 0.05
was considered as statistically significant.
5. Conclusions
In conclusion, this work demonstrates that celecoxib effectively blocks the emergence of multidrug
resistance by preventing the doxorubicin-induced upregulation of P-glycoprotein. We demonstrated
that doxorubicin treatment induces MDR in lymphoma cell lines, while addition of celecoxib inhibits
the development of resistance. Since celecoxib is not a Pgp inhibitor and the combination of the
two drugs did not increase toxicity, we conclude that celecoxib prevents the emergence of MDR by
interfering with Pgp expression. Our results show that the drug holiday effect can be mimicked in vitro
with a clinically used COX-2 inhibitor, offering a novel strategy to prolong response to therapy and to
delay or prevent the development of drug resistance. Based on these results a randomized double-blind
controlled study was initiated in the Veterinary Hematology and Oncology Clinic in Hungary.
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Table S1: Immunohistochemical findings of the two patients, Table S2: Detailed description of the used treatment
protocols, Table S3: Cell surface markers used for immunophenotyping CLBL-1 cells, Figure S1: The mRNA
expression of P388 cells after DOX treatment and following a drug holiday including data obtained from P388/ADR
cells (doxorubicin selected subline of P388), Figure S2: Cytotoxicity curves of P388 (a) and CLBL-1 (b) cells showing
drug sensitivity to doxorubicin (DOX), SAHA, trichostatin A (TSA), celecoxib (CEL), and firocoxib (FIR) for both
cell lines. Meloxicam (MEL) was tested only on CLBL-1 cells (b), Figure S3: Kaplan–Meier curves of cell cultures
including actual MAF values, Figure S4: Kaplan–Meier curves of cell cultures including days of repopulation time,
Supplementary materials 1: Cytology reports, Supplementary methods 1: Method of cytology sampling.
Author Contributions: Conceptualization, E.K., G.S., and A.F.; methodology, E.K., K.S., and A.F.; validation, E.K.,
K.S., P.V., G.S., and A.F.; investigation, E.K., S.F., E.S., V.D., T.W., P.V., and A.F.; resources, P.V., G.S., and A.F.;
writing—original draft preparation, E.K. and A.F.; writing—review and editing, E.K., K.S., P.V., G.S., and A.F.;
visualization, E.K., T.W., and A.F.; supervision, G.S., A.F., and P.V.; project administration, E.K. and A.F.; funding
acquisition, G.S. and A.F. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the National Research, Development, and Innovation Office of Hungary
(2019-1.3.1-KK-2019-00007 to G.S. and A.F.) and a Momentum Grant from the Hungarian Academy of Sciences (G.S.).
Cancers 2020, 12, 1117 12 of 16
Acknowledgments: We thank Judit Sessler, Szilárd Tóth, and the owners of the two canine patients. The in vitro
drug combination test system was developed by Szilárd Tóth. Dose–response curve fitting and calculation of IC50
values were performed by a custom program written by Judit Sessler in C#.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Stephen, W.; Vail, D.; Page, R. Withrow and MacEwen’s Small Animal Clinical Oncology—5th Edition.
Available online: https://www.elsevier.com/books/withrow-and-macewens-small-animal-clinical-oncology/
9781437723625 (accessed on 10 December 2018).
2. Fournel-Fleury, C.; Magnol, J.P.; Bricaire, P.; Marchal, T.; Chabanne, L.; Delverdier, A.; Bryon, P.A.; Felman, P.
Cytohistological and Immunological Classification of Canine Malignant Lymphomas: Comparison with
Human Non-Hodgkin’s Lymphomas. J. Comp. Pathol. 1997, 117, 35–59. [CrossRef]
3. Rütgen, B.C.; Hammer, S.E.; Gerner, W.; Christian, M.; de Arespacochaga, A.G.; Willmann, M.; Kleiter, M.;
Schwendenwein, I.; Saalmüller, A. Establishment and Characterization of a Novel Canine B-Cell Line Derived
from a Spontaneously Occurring Diffuse Large Cell Lymphoma. Leuk. Res. 2010, 34, 932–938. [CrossRef]
[PubMed]
4. Teske, E. Canine Malignant Lymphoma: A Review and Comparison with Human Non-Hodgkin’s Lymphoma.
Vet. Q. 1994, 16, 209–219. [CrossRef] [PubMed]
5. Marconato, L.; Gelain, M.E.; Comazzi, S. The Dog as a Possible Animal Model for Human Non-Hodgkin
Lymphoma: A Review. Hematol. Oncol. 2013, 31, 1–9. [CrossRef]
6. Dias, J.N.R.; Aguiar, S.I.; Pereira, D.M.; André, A.S.; Gano, L.; Correia, J.D.G.; Carrapiço, B.; Rütgen, B.;
Malhó, R.; Peleteiro, C.; et al. The Histone Deacetylase Inhibitor Panobinostat Is a Potent Antitumor Agent
in Canine Diffuse Large B-Cell Lymphoma. Oncotarget 2018, 9, 28586–28598. [CrossRef]
7. Kong, Y.; Barisone, G.A.; Sidhu, R.S.; O’Donnell, R.T.; Tuscano, J.M. Efficacy of Combined Histone Deacetylase
and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. Mol. Med. 2015, 21,
824–832. [CrossRef]
8. Zandvliet, M.M.J.M. Drug Resistance in Canine Multicentric Lymphoma. Available online: http://dspace.
library.uu.nl/handle/1874/313141 (accessed on 10 December 2018).
9. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters.
Nat. Rev. Cancer 2002, 2, 48–58. [CrossRef]
10. Mealey, K.L.; Barhoumi, R.; Rogers, K.; Kochevar, D.T. Doxorubicin Induced Expression of P-Glycoprotein in
a Canine Osteosarcoma Cell Line. Cancer Lett. 1998, 126, 187–192. [CrossRef]
11. Mealey, K.L.; Fidel, J. P-Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer.
J. Vet. Intern. Med. 2015, 29, 1–6. [CrossRef]
12. Vajdovich, P.; Koltai, Z.; Dékay, V.; Kungl, K.; Harnos, A. Evaluation of Pgp (MDR1) Immunohistochemistry
in Canine Lymphoma—Prognostic and Clinical Aspects. Acta Vet. Hung. 2018, 66, 309–328. [CrossRef]
13. Pawłowski, K.M.; Mucha, J.; Majchrzak, K.; Motyl, T.; Król, M. Expression and Role of PGP, BCRP, MRP1 and
MRP3 in Multidrug Resistance of Canine Mammary Cancer Cells. BMC Vet. Res. 2013, 9, 119. [CrossRef]
[PubMed]
14. Teng, S.-P.; Hsu, W.-L.; Chiu, C.-Y.; Wong, M.-L.; Chang, S.-C. Overexpression of P-Glycoprotein, STAT3,
Phospho-STAT3 and KIT in Spontaneous Canine Cutaneous Mast Cell Tumours before and after Prednisolone
Treatment. Vet. J. 2012, 193, 551–556. [CrossRef] [PubMed]
15. Kim, N.-H.; Hwang, Y.-H.; Im, K.-S.; Kim, J.-H.; Chon, S.-K.; Kim, H.-Y.; Sur, J.-H. P-Glycoprotein Expression
in Canine Mammary Gland Tumours Related with Myoepithelial Cells. Res. Vet. Sci. 2012, 93, 1346–1352.
[CrossRef]
16. Hifumi, T.; Miyoshi, N.; Kawaguchi, H.; Nomura, K.; Yasuda, N. Immunohistochemical Detection of Proteins
Associated with Multidrug Resistance to Anti-Cancer Drugs in Canine and Feline Primary Pulmonary
Carcinoma. J. Vet. Med. Sci. 2010, 72, 665–668. [CrossRef] [PubMed]
17. Lee, J.J.; Hughes, C.S.; Fine, R.L.; Page, R.L. P-Glycoprotein Expression in Canine Lymphoma: A Relevant,
Intermediate Model of Multidrug Resistance. Cancer 1996, 77, 1892–1898. [CrossRef]
18. Sokołowska, J.; Urban´ska, K.; Gizin´ski, S.; Zabielska, K.; Lechowski, R. Immunohistochemical Detection of
P-Glycoprotein in Various Subtypes of Canine Lymphomas. Pol. J. Vet. Sci. 2015, 18, 123–130. [CrossRef]
Cancers 2020, 12, 1117 13 of 16
19. Dékay, V.; Karai, E.; Szakács, G.; Füredi, A.; Szebényi, K.; Vajdovich, P. Calcein Assay for Multidrug Resistance
Predicts Therapy Response and Survival Rate in Canine Lymphoma Patients. 2020. in Preparation.
20. Lee, J.S.; Paull, K.; Alvarez, M.; Hose, C.; Monks, A.; Grever, M.; Fojo, A.T.; Bates, S.E. Rhodamine Efflux
Patterns Predict P-Glycoprotein Substrates in the National Cancer Institute Drug Screen. Mol. Pharmacol.
1994, 46, 627–638.
21. Legrand, O.; Simonin, G.; Perrot, J.Y.; Zittoun, R.; Marie, J.P. Pgp and MRP Activities Using Calcein-AM Are
Prognostic Factors in Adult Acute Myeloid Leukemia Patients. Blood 1998, 91, 4480–4488. [CrossRef]
22. Dhawan, A.; Nichol, D.; Kinose, F.; Abazeed, M.E.; Marusyk, A.; Haura, E.B.; Scott, J.G. Collateral Sensitivity
Networks Reveal Evolutionary Instability and Novel Treatment Strategies in ALK Mutated Non-Small Cell
Lung Cancer. Sci. Rep. 2017, 7, 1232. [CrossRef]
23. Becker, A.; Crombag, L.; Heideman, D.A.M.; Thunnissen, F.B.; van Wijk, A.W.; Postmus, P.E.; Smit, E.F.
Retreatment with Erlotinib: Regain of TKI Sensitivity Following a Drug Holiday for Patients with NSCLC
Who Initially Responded to EGFR-TKI Treatment. Eur. J. Cancer 2011, 47, 2603–2606. [CrossRef] [PubMed]
24. Pisco, A.O.; Brock, A.; Zhou, J.; Moor, A.; Mojtahedi, M.; Jackson, D.; Huang, S. Non-Darwinian Dynamics in
Therapy-Induced Cancer Drug Resistance. Nat. Commun. 2013, 4, 2467. [CrossRef] [PubMed]
25. Knoechel, B.; Roderick, J.E.; Williamson, K.E.; Zhu, J.; Lohr, J.G.; Cotton, M.J.; Gillespie, S.M.; Fernandez, D.;
Ku, M.; Wang, H.; et al. An Epigenetic Mechanism of Resistance to Targeted Therapy in T Cell Acute
Lymphoblastic Leukemia. Nat. Genet. 2014, 46, 364–370. [CrossRef] [PubMed]
26. Moyal, L.; Feldbaum, N.; Goldfeiz, N.; Rephaeli, A.; Nudelman, A.; Weitman, M.; Tarasenko, N.; Gorovitz, B.;
Maron, L.; Yehezkel, S.; et al. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for
Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. PLoS ONE 2016, 11, e0146115.
[CrossRef] [PubMed]
27. Chun, P. Histone Deacetylase Inhibitors in Hematological Malignancies and Solid Tumors. Arch. Pharm. Res.
2015, 38, 933–949. [CrossRef] [PubMed]
28. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone Deacetylase Inhibitors: Molecular Mechanisms of Action.
Oncogene 2007, 26, 5541–5552. [CrossRef]
29. Mackmull, M.-T.; Iskar, M.; Parca, L.; Singer, S.; Bork, P.; Ori, A.; Beck, M. Histone Deacetylase Inhibitors
(HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs). Mol. Cell. Proteom.
2015, 14, 1350–1360. [CrossRef]
30. Vimal, A.P.; Dunn, M.J.; Sorokin, A. Regulation of MDR-1 (P-Glycoprotein) by
Cyclooxygenase-2.—PubMed—NCBI. Available online: https://www.ncbi.nlm.nih.gov/pubmed/12138126
(accessed on 18 November 2019).
31. Karászi, E.; Jakab, K.; Homolya, L.; Szakács, G.; Holló, Z.; Telek, B.; Kiss, A.; Rejtô, L.; Nahajevszky, S.;
Sarkadi, B.; et al. Calcein Assay for Multidrug Resistance Reliably Predicts Therapy Response and Survival
Rate in Acute Myeloid Leukaemia. Br. J. Haematol. 2001, 112, 308–314. [CrossRef]
32. Lebedeva, I.V.; Pande, P.; Patton, W.F. Sensitive and Specific Fluorescent Probes for Functional Analysis of
the Three Major Types of Mammalian ABC Transporters. PLoS ONE 2011, 6, e22429. [CrossRef]
33. Schabel, F.M.; Skipper, H.E.; Trader, M.W.; Laster, W.R.; Griswold, D.P.; Corbett, T.H. Establishment of
Cross-Resistance Profiles for New Agents. Cancer Treat. Rep. 1983, 67, 905–922.
34. Zandvliet, M.; Teske, E.; Schrickx, J.A. Multi-Drug Resistance in a Canine Lymphoid Cell Line Due to
Increased P-Glycoprotein Expression, a Potential Model for Drug-Resistant Canine Lymphoma. Toxicol. Vitro
2014, 28, 1498–1506. [CrossRef] [PubMed]
35. Moore, A.S.; Leveille, C.R.; Reimann, K.A.; Shu, H.; Arias, I.M. The Expression of P-Glycoprotein in Canine
Lymphoma and Its Association with Multidrug Resistance. Cancer Investig. 1995, 13, 475–479. [CrossRef]
[PubMed]
36. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug Resistance in
Cancer: An Overview. Cancers (Basel) 2014, 6, 1769–1792. [CrossRef] [PubMed]
37. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 Pharmacogenetics and Cancer. Oncogene
2006, 25, 1679–1691. [CrossRef] [PubMed]
38. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.;
Tenen, D.G.; Halmos, B. EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. N. Engl.
J. Med. 2005, 352, 786–792. [CrossRef] [PubMed]
Cancers 2020, 12, 1117 14 of 16
39. Olaussen, K.A.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; Taranchon, E.; Filipits, M.;
Pirker, R.; Popper, H.H.; et al. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based
Adjuvant Chemotherapy. N. Engl. J. Med. 2006, 355, 983–991. [CrossRef] [PubMed]
40. Reed, J.C. Bcl-2: Prevention of Apoptosis as a Mechanism of Drug Resistance. Hematol. Oncol. Clin. N. Am.
1995, 9, 451–473. [CrossRef]
41. Singh, A.; Settleman, J. EMT, Cancer Stem Cells and Drug Resistance: An Emerging Axis of Evil in the War
on Cancer. Oncogene 2010, 29, 4741–4751. [CrossRef]
42. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.;
Zou, L.; Fischbach, M.A.; et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell
Subpopulations. Cell 2010, 141, 69–80. [CrossRef]
43. Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the Role of ABC
Transporters in Multidrug-Resistant Cancer. Nat. Rev. Cancer 2018, 18, 452–464. [CrossRef]
44. Pirker, R.; Wallner, J.; Götzl, M.; Gsur, A.; Geissler, K.; Havelec, L.; Knapp, W.; Haas, O.; Linkesch, W.;
Lechner, K. MDR1 RNA Expression Is an Independent Prognostic Factor in Acute Myeloid Leukemia. Blood
1992, 80, 557–559. [CrossRef] [PubMed]
45. Doxani, C.; Voulgarelis, M.; Zintzaras, E. MDR1 MRNA Expression and MDR1 Gene Variants as Predictors
of Response to Chemotherapy in Patients with Acute Myeloid Leukaemia: A Meta-Analysis. Biomarkers
2013, 18, 425–435. [CrossRef] [PubMed]
46. Campos, L.; Guyotat, D.; Archimbaud, E.; Calmard-Oriol, P.; Tsuruo, T.; Troncy, J.; Treille, D.; Fiere, D. Clinical
Significance of Multidrug Resistance P-Glycoprotein Expression on Acute Nonlymphoblastic Leukemia
Cells at Diagnosis. Blood 1992, 79, 473–476. [CrossRef] [PubMed]
47. Gillet, J.-P.; Wang, J.; Calcagno, A.M.; Green, L.J.; Varma, S.; Elstrand, M.B.; Trope, C.G.; Ambudkar, S.V.;
Davidson, B.; Gottesman, M.M. Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian
Serous Carcinoma Effusions. Mol. Pharm. 2011, 8, 2080–2088. [CrossRef] [PubMed]
48. Christie, E.L.; Pattnaik, S.; Beach, J.; Copeland, A.; Rashoo, N.; Fereday, S.; Hendley, J.; Alsop, K.; Brady, S.L.;
Lamb, G.; et al. Multiple ABCB1 Transcriptional Fusions in Drug Resistant High-Grade Serous Ovarian and
Breast Cancer. Nat. Commun. 2019, 10, 1295. [CrossRef] [PubMed]
49. Coyle, B.; Kessler, M.; Sabnis, D.H.; Kerr, I.D. ABCB1 in Children’s Brain Tumours. Biochem. Soc. Trans. 2015,
43, 1018–1022. [CrossRef]
50. Othman, R.T.; Kimishi, I.; Bradshaw, T.D.; Storer, L.C.D.; Korshunov, A.; Pfister, S.M.; Grundy, R.G.; Kerr, I.D.;
Coyle, B. Overcoming Multiple Drug Resistance Mechanisms in Medulloblastoma. Acta Neuropathol. Commun.
2014, 2, 57. [CrossRef]
51. Luo, Y.; Ellis, L.Z.; Dallaglio, K.; Takeda, M.; Robinson, W.A.; Robinson, S.E.; Liu, W.; Lewis, K.D.;
McCarter, M.D.; Gonzalez, R.; et al. Side Population Cells from Human Melanoma Tumors Reveal Diverse
Mechanisms for Chemoresistance. J. Investig. Dermatol. 2012, 132, 2440–2450. [CrossRef]
52. Effendi, K.; Mori, T.; Komuta, M.; Masugi, Y.; Du, W.; Sakamoto, M. Bmi-1 Gene Is Upregulated in Early-Stage
Hepatocellular Carcinoma and Correlates with ATP-Binding Cassette Transporter B1 Expression. Cancer Sci.
2010, 101, 666–672. [CrossRef]
53. Rottenberg, S.; Nygren, A.O.H.; Pajic, M.; van Leeuwen, F.W.B.; van der Heijden, I.; van de Wetering, K.;
Liu, X.; de Visser, K.E.; Gilhuijs, K.G.; van Tellingen, O.; et al. Selective Induction of Chemotherapy Resistance
of Mammary Tumors in a Conditional Mouse Model for Hereditary Breast Cancer. Proc. Natl. Acad. Sci. USA
2007, 104, 12117–12122. [CrossRef]
54. Pajic, M.; Iyer, J.K.; Kersbergen, A.; van der Burg, E.; Nygren, A.O.H.; Jonkers, J.; Borst, P.; Rottenberg, S.
Moderate Increase in Mdr1a/1b Expression Causes in Vivo Resistance to Doxorubicin in a Mouse Model for
Hereditary Breast Cancer. Cancer Res. 2009, 69, 6396–6404. [CrossRef] [PubMed]
55. Rottenberg, S.; Vollebergh, M.A.; de Hoon, B.; de Ronde, J.; Schouten, P.C.; Kersbergen, A.; Zander, S.A.L.;
Pajic, M.; Jaspers, J.E.; Jonkers, M.; et al. Impact of Intertumoral Heterogeneity on Predicting Chemotherapy
Response of BRCA1-Deficient Mammary Tumors. Cancer Res. 2012, 72, 2350–2361. [CrossRef] [PubMed]
56. Füredi, A.; Tóth, S.; Szebényi, K.; Pape, V.F.S.; Türk, D.; Kucsma, N.; Cervenak, L.; Tóvári, J.; Szakács, G.
Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell
Line-Specific Effects from P-Glycoprotein-Induced Toxicity. Mol. Cancer Ther. 2017, 16, 45–56. [CrossRef]
Cancers 2020, 12, 1117 15 of 16
57. Füredi, A.; Szebényi, K.; Tóth, S.; Cserepes, M.; Hámori, L.; Nagy, V.; Karai, E.; Vajdovich, P.; Imre, T.;
Szabó, P.; et al. Pegylated Liposomal Formulation of Doxorubicin Overcomes Drug Resistance in a Genetically
Engineered Mouse Model of Breast Cancer. J. Control. Release 2017, 261, 287–296. [CrossRef]
58. Homolya, L.; Holló, Z.; Germann, U.A.; Pastan, I.; Gottesman, M.M.; Sarkadi, B. Fluorescent Cellular
Indicators Are Extruded by the Multidrug Resistance Protein. J. Biol. Chem. 1993, 268, 21493–21496.
59. Homolya, L.; Holló, M.; Müller, M.; Mechetner, E.B.; Sarkadi, B. A New Method for a Quantitative Assessment
of P-Glycoprotein-Related Multidrug Resistance in Tumor Cells. Br. J. Cancer 1996, 73, 849–855. [CrossRef]
60. Kurata, T.; Tamura, K.; Kaneda, H.; Nogami, T.; Uejima, H.; Go, G.O.A.; Nakagawa, K.; Fukuoka, M. Effect
of Re-Treatment with Gefitinib (“Iressa”, ZD1839) after Acquisition of Resistance. Ann. Oncol. 2004, 15,
173–174. [CrossRef]
61. Yano, S.; Nakataki, E.; Ohtsuka, S.; Inayama, M.; Tomimoto, H.; Edakuni, N.; Kakiuchi, S.; Nishikubo, N.;
Muguruma, H.; Sone, S. Retreatment of Lung Adenocarcinoma Patients with Gefitinib Who Had Experienced
Favorable Results from Their Initial Treatment with This Selective Epidermal Growth Factor Receptor
Inhibitor: A Report of Three Cases. Oncol. Res. 2005, 15, 107–111. [CrossRef]
62. Valpione, S.; Carlino, M.S.; Mangana, J.; Mooradian, M.J.; McArthur, G.; Schadendorf, D.; Hauschild, A.;
Menzies, A.M.; Arance, A.; Ascierto, P.A.; et al. Rechallenge with BRAF-Directed Treatment in Metastatic
Melanoma: A Multi-Institutional Retrospective Study. Eur. J. Cancer 2018, 91, 116–124. [CrossRef]
63. Cara, S.; Tannock, I.F. Retreatment of Patients with the Same Chemotherapy: Implications for Clinical
Mechanisms of Drug Resistance. Ann. Oncol. 2001, 12, 23–27. [CrossRef]
64. Harker, W.G.; Sikic, B.I. Multidrug (Pleiotropic) Resistance in Doxorubicin-Selected Variants of the Human
Sarcoma Cell Line MES-SA. Cancer Res. 1985, 45, 4091–4096. [PubMed]
65. Shen, D.W.; Cardarelli, C.; Hwang, J.; Cornwell, M.; Richert, N.; Ishii, S.; Pastan, I.; Gottesman, M.M. Multiple
Drug-Resistant Human KB Carcinoma Cells Independently Selected for High-Level Resistance to Colchicine,
Adriamycin, or Vinblastine Show Changes in Expression of Specific Proteins. J. Biol. Chem. 1986, 261,
7762–7770. [PubMed]
66. Ageberg, M.; Rydström, K.; Relander, T.; Drott, K. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes
Diffuse Large B-Cell Lymphoma Cell Lines to CHOP-Induced Cell Death. Am. J. Transl. Res. 2013, 5, 170–183.
[PubMed]
67. Pang, L.Y.; Argyle, S.A.; Kamida, A.; Morrison, K.O.; Argyle, D.J. The Long-Acting COX-2 Inhibitor
Mavacoxib (TrocoxilTM) Has Anti-Proliferative and pro-Apoptotic Effects on Canine Cancer Cell Lines and
Cancer Stem Cells in Vitro. BMC Vet. Res. 2014, 10, 184. [CrossRef]
68. Knottenbelt, C.; Chambers, G.; Gault, E.; Argyle, D.J. The in Vitro Effects of Piroxicam and Meloxicam on
Canine Cell Lines. J. Small Anim. Pract. 2006, 47, 14–20. [CrossRef]
69. Murakami, A.; Shibahashi, A.; Iwasaki, R.; Kawabe, M.; Murakami, M.; Sakai, H.; Mori, T. Combination
Chlorambucil/Firocoxib or Chlorambucil/Prednisolone Treatment for Inflammatory Colorectal Polyps in
Miniature Dachshunds. J. Am. Anim. Hosp. Assoc. 2018, 54, 161–166. [CrossRef]
70. Tamura, D.; Saito, T.; Murata, K.; Kawashima, M.; Asano, R. Celecoxib Exerts Antitumor Effects in Canine
Mammary Tumor Cells via COX-2-independent Mechanisms. Int. J. Oncol. 2015, 46, 1393–1404. [CrossRef]
71. Fantappiè, O.; Solazzo, M.; Lasagna, N.; Platini, F.; Tessitore, L.; Mazzanti, R. P-Glycoprotein Mediates
Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines. Cancer Res. 2007, 67, 4915–4923.
[CrossRef]
72. Ratnasinghe, D.; Daschner, P.J.; Anver, M.R.; Kasprzak, B.H.; Taylor, P.R.; Yeh, G.C.; Tangrea, J.A.
Cyclooxygenase-2, P-Glycoprotein-170 and Drug Resistance; Is Chemoprevention against Multidrug
Resistance Possible? Anticancer Res. 2001, 21, 2141–2147.
73. Sui, H.; Zhou, S.; Wang, Y.; Liu, X.; Zhou, L.; Yin, P.; Fan, Z.; Li, Q. COX-2 Contributes to
P-Glycoprotein-Mediated Multidrug Resistance via Phosphorylation of c-Jun at Ser63/73 in Colorectal
Cancer. Carcinogenesis 2011, 32, 667–675. [CrossRef]
74. Roy, K.R.; Reddy, G.V.; Maitreyi, L.; Agarwal, S.; Achari, C.; Vali, S.; Reddanna, P. Celecoxib Inhibits MDR1
Expression through COX-2-Dependent Mechanism in Human Hepatocellular Carcinoma (HepG2) Cell Line.
Cancer Chemother. Pharmacol. 2010, 65, 903–911. [CrossRef] [PubMed]
75. Knudsen, J.F.; Carlsson, U.; Hammarström, P.; Sokol, G.H.; Cantilena, L.R. The Cyclooxygenase-2 Inhibitor
Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II. Inflammation 2004, 28, 285–290. [CrossRef]
[PubMed]
Cancers 2020, 12, 1117 16 of 16
76. Arico, S.; Pattingre, S.; Bauvy, C.; Gane, P.; Barbat, A.; Codogno, P.; Ogier-Denis, E. Celecoxib Induces
Apoptosis by Inhibiting 3-Phosphoinositide-Dependent Protein Kinase-1 Activity in the Human Colon
Cancer HT-29 Cell Line. J. Biol. Chem. 2002, 277, 27613–27621. [CrossRef] [PubMed]
77. Kulp, S.K.; Yang, Y.-T.; Hung, C.-C.; Chen, K.-F.; Lai, J.-P.; Tseng, P.-H.; Fowble, J.W.;
Ward, P.J.; Chen, C.-S. 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major
Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells. Cancer Res. 2004, 64, 1444–1451.
[CrossRef] [PubMed]
78. Johnson, A.J.; Hsu, A.-L.; Lin, H.-P.; Song, X.; Chen, C.-S. The Cyclo-Oxygenase-2 Inhibitor Celecoxib
Perturbs Intracellular Calcium by Inhibiting Endoplasmic Reticulum Ca2+-ATPases: A Plausible Link with
Its Anti-Tumor Effect and Cardiovascular Risks. Biochem. J. 2002, 366 Pt 3, 831–837. [CrossRef] [PubMed]
79. Chou, T.-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and
Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006, 58, 621–681. [CrossRef]
80. Holló, Z.; Homolya, L.; Davis, C.W.; Sarkadi, B. Calcein Accumulation as a Fluorometric Functional Assay of
the Multidrug Transporter. Biochim. Biophys. Acta Biomembr. 1994, 1191, 384–388. [CrossRef]
81. Stone, M.S.; Cotter, S.M.; Goldstein, M.A. Comparison of Two Protocols for Induction of Remission in Dogs
with Lymphoma. J. Am. Anim. Hosp. 1991, 27, 315–321.
82. Valli, V.E.; Kass, P.H.; Myint, M.S.; Scott, F. Canine Lymphomas: Association of Classification Type, Disease
Stage, Tumor Subtype, Mitotic Rate, and Treatment with Survival. Vet. Pathol. 2013, 50, 738–748. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
